Anti-macrophage migration inhibitory factor (anti-mif) antibody (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01541670 (ClinicalTrials.gov) | November 2011 | 20/2/2012 | Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis | A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis | Systemic Lupus Erythematosus | Drug: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody | Baxalta now part of Shire | NULL | Terminated | 18 Years | N/A | All | 4 | Phase 1 | United States;Australia;Canada;Mexico;New Zealand |